251 related articles for article (PubMed ID: 28594755)
21. Attitudes toward long-acting reversible contraception among young women seeking abortion.
Rose SB; Cooper AJ; Baker NK; Lawton B
J Womens Health (Larchmt); 2011 Nov; 20(11):1729-35. PubMed ID: 21923281
[TBL] [Abstract][Full Text] [Related]
22. Uptake and adherence to long-acting reversible contraception post-abortion.
Rose SB; Lawton BA; Brown SA
Contraception; 2010 Oct; 82(4):345-53. PubMed ID: 20851228
[TBL] [Abstract][Full Text] [Related]
23. Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States.
Upadhyay UD; Zlidar VM; Foster DG
Contraception; 2016 Oct; 94(4):303-13. PubMed ID: 27326938
[TBL] [Abstract][Full Text] [Related]
24. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
[TBL] [Abstract][Full Text] [Related]
25. Plan A: postabortion contraception.
Micks E; Prager S
Clin Obstet Gynecol; 2014 Dec; 57(4):751-62. PubMed ID: 25254920
[TBL] [Abstract][Full Text] [Related]
26. Postabortion Initiation of Long-Acting Reversible Contraception by Adolescent and Nulliparous Women in New Zealand.
Rose SB; Garrett SM
J Adolesc Health; 2016 Feb; 58(2):160-6. PubMed ID: 26603946
[TBL] [Abstract][Full Text] [Related]
27. Depot-medroxyprogesterone acetate contraception use among Salvadoran women: an in-depth analysis of attitudes and experiences.
Cremer M; Ditzian L; April A; Peralta E; Klausner D; Podolsky R; Dierking E
J Womens Health (Larchmt); 2011 Nov; 20(11):1751-6. PubMed ID: 21823919
[TBL] [Abstract][Full Text] [Related]
28. Immediate postabortion access to IUDs, implants and DMPA reduces repeat pregnancy within 1 year in a New York City practice.
Langston AM; Joslin-Roher SL; Westhoff CL
Contraception; 2014 Feb; 89(2):103-8. PubMed ID: 24309218
[TBL] [Abstract][Full Text] [Related]
29. Depot medroxyprogesterone acetate contraception in women with medical problems.
Frederiksen MC
J Reprod Med; 1996 May; 41(5 Suppl):414-8. PubMed ID: 8725704
[TBL] [Abstract][Full Text] [Related]
30. The Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception.
Secura GM; Allsworth JE; Madden T; Mullersman JL; Peipert JF
Am J Obstet Gynecol; 2010 Aug; 203(2):115.e1-7. PubMed ID: 20541171
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of long-acting reversible contraception.
Winner B; Peipert JF; Zhao Q; Buckel C; Madden T; Allsworth JE; Secura GM
N Engl J Med; 2012 May; 366(21):1998-2007. PubMed ID: 22621627
[TBL] [Abstract][Full Text] [Related]
32. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population.
Polaneczky M; Guarnaccia M; Alon J; Wiley J
Fam Plann Perspect; 1996; 28(4):174-8. PubMed ID: 8853283
[TBL] [Abstract][Full Text] [Related]
33. A cross-sectional study of the forearm bone mineral density in long-term current users of the injectable contraceptive depot medroxyprogesterone acetate.
Viola AS; Castro S; Bahamondes MV; Fernandes A; Viola CF; Bahamondes L
Contraception; 2011 Nov; 84(5):e31-7. PubMed ID: 22018135
[TBL] [Abstract][Full Text] [Related]
34. Depo Provera. Position paper on clinical use, effectiveness and side effects.
Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
[TBL] [Abstract][Full Text] [Related]
35. The influence of trust in health care systems on postabortion contraceptive choice.
Stacey RE; Dempsey A
Contraception; 2015 Nov; 92(5):458-62. PubMed ID: 26197264
[TBL] [Abstract][Full Text] [Related]
36. Effect of previous induced abortions on postabortion contraception selection.
Keene M; Roston A; Keith L; Patel A
Contraception; 2015 May; 91(5):398-402. PubMed ID: 25637863
[TBL] [Abstract][Full Text] [Related]
37. Post-abortion depot medroxyprogesterone acetate continuation rates: a randomized trial of cyclic estradiol.
Goldberg AB; Cardenas LH; Hubbard AE; Darney PD
Contraception; 2002 Oct; 66(4):215-20. PubMed ID: 12413614
[TBL] [Abstract][Full Text] [Related]
38. Intra-abortion contraception with etonogestrel subdermal implant.
Barros Pereira I; Carvalho RM; Graça LM
Eur J Obstet Gynecol Reprod Biol; 2015 Feb; 185():33-5. PubMed ID: 25522115
[TBL] [Abstract][Full Text] [Related]
39. Does the type of abortion provider influence contraceptive uptake after abortion? An analysis of longitudinal data from 64 health facilities in Ghana.
Maxwell L; Voetagbe G; Paul M; Mark A
BMC Public Health; 2015 Jun; 15():586. PubMed ID: 26104025
[TBL] [Abstract][Full Text] [Related]
40. Long-Acting Reversible Contraceptive Uptake before and after the Affordable Care Act Contraceptive Mandate in Women Undergoing First Trimester Surgical Abortion.
Bell KN; Meyn LA; Chen BA
Womens Health Issues; 2018; 28(4):301-305. PubMed ID: 29853173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
